LP
NMRA icon

LMR Partners’s Neumora Therapeutics NMRA Stock Holding History

LMR Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-616,400
Closed -$6.53M – 1560
2024
Q4 		$6.53M Buy
616,400
+514,900
+507% +$6.17M 0.05% 325
2024
Q3 		$1.34M Buy
+101,500
New +$1.18M 0.01% 691

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

LMR Partners's NMRA Position: Q2 2024 in Review

LMR Partners sold out of Neumora Therapeutics (NMRA) in Q2 2024, closing a stake of 187,811 shares — an estimated $2.58M sold.

LMR Partners first reported a position in NMRA in Q1 2024 and held it in 1 quarter. The position peaked at $2.58M in Q1 2024. 93 funds tracked by Wall St. Rank hold NMRA as of Q2 2024.

  • LMR Partners reported no remaining Neumora Therapeutics position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 187,811 Neumora Therapeutics shares in Q2 2024, an estimated $2.58M.
  • LMR Partners first reported a position in Neumora Therapeutics in Q1 2024 and held it in 1 quarter.
  • LMR Partners's Neumora Therapeutics position peaked at $2.58M in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.